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Identifying, managing and supporting patients with a rare 
disease  
 
Rare diseases (RDs) are defined as diseases that affect fewer than 1 in 2000 
people, 71.9% are genetic and 69.9% have symptom onset in childhood. 
There are an estimated 8000 rare diseases, and although individually rare, 
collectively they are common, with an estimated combined prevalence of 3.5-
5.9%, similar to diseases such as asthma and diabetes.  Although rare 
diseases may be considered the domain of specialists, the identification, 
management and support of ‘rare disease’ patients and their families falls 




Of the 8000 RDs, 100 diseases account  for 80% of  patients with RDs (see 
figure 1). RDs include familiar diseases, such as cystic fibrosis and 
haemophilia, and ultra-rare diseases, defined as affecting fewer than 1 in 




Rare diseases are also referred to as orphan or neglected diseases reflecting 
the frequent paucity of information about the diseases, as well as a lack of 
treatments and research.   This problem is globally acknowledged and 
although there is a long way to go, efforts to improve the outcomes for these 
patients are in place. Vocal and influential patient advocacy groups have led 
to change. The UK strategy for rare disease published in 2013, with more 
recent updates, clarifies the challenges and sets out a pathway to improve 
outcomes ‘to ensure no one gets left behind just because they have a rare 
disease’ (Department of Health and Social Care, 2020; Department of Health, 
2013). Emerging technologies in both diagnostics and therapeutics have also 
improved the outcomes for many rare disease patients, with molecular 
diagnoses more accurately defining their problem and facilitating better 
treatments. Incentives for drug development and profitability, despite the small 
market, have led to an increasing number of approved drugs for RDs (EMA, 
E.M.A., 2020). Despite the breadth and number of rare diseases many issues 




When to suspect a rare disease? 
Frequently patients with RDs spend many years, or even decades, on their 
route to a diagnosis. This ‘diagnostic odyssey’, involves multiple referrals, 
investigations, and misdiagnoses, with many patients never receiving an 
accurate diagnosis. During this ‘odyssey’ patients receive inappropriate 
treatments, suffer from the consequences of disease progression and report 
the emotional distress of having unanswered questions and at times the 
legitimacy of their symptoms questioned. This is all at great burden and 
financial cost to the patient and the health care system (Eurordis, 2009). 
Indeed, frequent attendance in primary care can be considered a ‘red flag’ for 
an undiagnosed rare disease. 
Even in the absence of a disease specific treatment, an accurate diagnosis is 
of immense benefit to the patient and their families. It enables the optimisation 
of their management, access to specialist care, the support of patient 
advocacy groups, access to clinical trials and emerging therapies, and 
importantly a diagnostic label and validation for their problems or experiences. 
Indeed, gaining access to health, educational and social support without 
accurate diagnosis (and something to put in the ‘diagnostic box’), is incredibly 
difficult. Diagnosis can also herald the end of unbeneficial diagnostics, 
monitoring and treatment. 
 
But how can a single clinician know about 8000 diseases? The short answer 
is, they can’t. However, GPs can help. We offer whole patient care, are one of 
the few generalists working in the NHS and have continuity of clinical record 
over the life of the patients. We are familiar with excluding the rare amongst 
the common, excluding significant infections and cancers we may only see a 
handful of times in our career, and are well placed to see the broader clinical 
picture. We can join the dots spread both across the biology of the patient and 
the chronology of their record that may be missed by secondary care 
colleagues working in specialist ‘siloes’ (Evans & Rafi, 2016). An inquisitive 
mind and the use of ‘gut feeling’ when patterns diverge from the norm should 
be a prompt for further enquiry (de Vries et al, 2018), with ‘Family GENES’ a 




Certain scenarios are enriched with patients who may have an undiagnosed 
rare disease, including when multiple umbrella terms are used as diagnoses 
(e.g. learning disability, epilepsy, cerebral palsy) (Crowe et al, 2020). Ask 
yourself, does the umbrella term account for the full clinical picture? Or is the 
umbrella term capturing just one component of what is a much longer list of 
problems that the patient has? 
 
 
Information about the patient’s family history, can alert the GP to rare disease. 
GPs frequently are aware of the extended families registered at their practice, 
particularly in closely-knit communities. Collecting a family history has formed 
an integral part of general practice for decades (Qureshi et al. 2004; Zander et 
al. 1978), with this information typically collected at opportunities such as 
registration with the practice, prescribing contraceptives and during 
cardiovascular health checks. In genomics knowledge of a patient’s health 
issues frequently impacts other family members. In the absence of the 
patient’s explicit consent to share such information the clinician may find 
themselves in a difficult situation, balancing their duty to protect 
confidentiality, with the risk of causing harm to another family member. In 
primary care these scenarios are infrequent and if encountered, guidance 
should be taken, but a key message is that confidentiality is not absolute and 
breaches of confidentiality can be made in certain situations where significant 
risk may occur to another person (Middleton et al, 2020). Patterns of 
inheritance typically reflect the diseases that may appear in a comprehensive 
family history. Autosomal dominant conditions may be recognised by similar 
characteristics presenting in each generation, for example grandparents, 
uncles and cousins with abnormal limb movements may indicate Huntington’s 
disease. Many rare diseases follow an autosomal recessive inheritance 
pattern and therefore may be difficult to identify from the family history. The 
exception is when parents and other couples in the close family are related to 
each other before marriage, for example cousins. We are all carriers for more 
than 20 of the approximately 1800 autosomal recessive disorders, however 
typically, pathogenic variants in the same gene are not inherited from both 
parents (Antonarakis, 2019). When there are consanguineous marital 
patterns, practised in several minority communities in the UK, there is an 
increased likelihood that the same pathogenic variants are inherited from both 
parents. Similar clinical features in several members of these families may 
indicate a rare recessive disorder e.g. childhood onset visual or hearing loss, 
learning disabilities or recurrent stillbirths. It may be perceived as challenging 
to take a detailed family history in these patients, due to cultural sensitivities 
and sometimes language barriers. Is this something you would feel able to 
do?   
 
When clinical suspicions are heightened there are several resources available 
to help guide a problem-based search for differential diagnoses (see Box 2). 
These differential diagnoses can help guide subsequent investigation or 
referral, with advice often readily available through clinical genetics 
departments or, if an inherited metabolic disease is suspected, the local 




Clinical case scenario 1 
Salma is 22 years old and comes to see you with her mother and sister with 
an episode of acute sinusitis. Her family moved to the UK from Yemen 6 
years ago. She has mild learning difficulties and well-controlled epilepsy; 
Mum attributes these problems to “being dropped on her head when she 
was a baby”. You note from her records that in addition to lamotrigine, she 
is on long-term calcium and vitamin d supplementation following an episode 
of hypocalcaemia 4 years ago. You examine Salma and incidentally note 
that her facial features, although subtle, are quite different to her mother’s 
and sister’s. You advise that sinusitis is a self-limiting condition and 
symptomatic management is all that is required, and when to return to see 
you if it doesn’t resolve or worsens. You make a note to yourself to explore 
her records more thoroughly at the end of the surgery, as her past history 
doesn’t make sense to you. 
On review of her notes you note she was seen once by neurology after 
arriving in the UK, the letter comments on the learning disability and a CT 
head was performed which was normal. You reflect on her combination of 
symptoms and her subtle facial dysmorphology and feel there may be a 
genetic syndrome to explain her problems. You input her clinical features 
into an online rare disease search engine and it gives 22q11.2 deletion 
syndrome (see figure 2), a chromosomal anomaly that can be identified by 
microarray, as a differential diagnosis. You feel this is plausible.  
What would you do next? How would you approach and discuss this with 
Salma and her mother about your suspicions?  How might you take into 





Investigation and referral 
 
Having identified features that suggest a rare disease a step-wise approach 
should be adopted to refine clinical suspicions and the appropriate next steps. 
This may involve initial investigations in primary care and referral into 
appropriate local pathways.  
For example, tests that may be performed in primary care include: 
• An elevated creatine kinase (CK) level for someone with myalgia in a 
range of inflammatory and metabolic muscular disorders. 
• Abnormalities in electrolytes and a morning cortisol level for Addison’s 
disease. 
• Abnormality in the lipid profile for metabolic conditions such as familial 
hypercholesterolemia. 
 
Few genomic tests can be directly requested in primary care. Referral offers 
the opportunity to clarify or confirm the diagnosis, with more focussed 
assessments and genomic testing available in clinical genetics and in 
specified clinical scenarios other specialties. Which genomic tests are 
commissioned by the NHS in England, when they should be performed and 
by whom has been standardised as part of the National Genomic Test 
Directory, and might include a chromosome analysis (microarray), single gene 
testing (e.g. in cystic fibrosis), and next generation sequencing (gene panels, 
whole exome or genome sequencing (WES/WGS).  
GPs will be exposed to rare metabolic diseases through new-born screening 
(NBS). In the UK this screening involves testing for 9 rare diseases (see Box 
3), measuring the metabolites or enzyme level in a dried blood spot from the 
heel prick test. Subsequent definitive testing is performed on abnormal 
results, in an often time critical manner. The adoption of diseases for inclusion 
is at the discretion of the UK National Screening Committee. Although the 
number of diseases has grown, there is significant international variability, 
with 40 diseases screened for in Italy and in the US 35 mandated, with some 




With significant advances in genomics and adoption of testing, an important 
consideration for primary care is when patients previously investigated, often 
as a child, and discharged to primary care for symptomatic management, 
should be referred back (or not) for a further attempt at establishing a 
diagnosis. For example, Microarray, also sometimes referred to as an array 
CGH, is now widely used, frequently by paediatricians, as the first tier genetic 
test for patients with intellectual disability, congenital anomalies, dysmorphism 
and developmental delay. It can identify copy number variants (CNV), missing 
or duplicated segments of chromosomes, which are frequently the aetiology of 
these disorders (for a further explanation of microarray please refer to the 
Unique web page detailed in the resources (Box 4)). The national genetic 
testing directory advises which test should be performed in which clinical 
scenario and advises whole exome sequencing (WES) for unexplained 
congenital malformations, unexplained intellectual disability and global 
developmental delay often following a microarray and whole genome 
sequencing (WGS) for suspected ultra rare or atypical monogenic disorders. 
The additional diagnostic yield of these technologies for rare diseases can be 
substantial. In NHS England’s 100,000 Genome Project, a cohort of rare 
disease patients who had been extensively investigated by multiple other 
methods prior to enrolment, WGS achieved a diagnosis in 26% of rare 
disease patients and for those with intellectual disability 37%.  
The decision making for whether to refer back or not is multifaceted involving 
the current level of disability, likelihood of benefit to the patient and the wishes 
of the patient and their family. Would you feel able to have such a discussion? 
Do you know where your local genetic departments are and if there are local 
referral protocols? 
 
Clinical case scenario 2 
Sarah is 28-years-old and comes to see you for preconception advice. She 
asks whether she should have a test for cystic fibrosis (CF) because her 
partner Dave is known to be a carrier and Dave’s older brother died of CF 
when he was 17. (see figure 3) She wants to know what her risk of having a 
baby with CF is. What would you tell her? 
She decides that she would like to be tested. What should you do next? 
You review the National Genomic Test Directory and identify that one of the 
criteria for CF carrier testing is 'partner of a known CF carrier'. In your 
region there is a protocol to enable CF carrier testing in primary care for this 
indication. 
You clarify with the laboratory what sample is needed, typically a blood test 
in an EDTA (purple) topped bottle, and that it takes approximately 2 weeks 
for a test result. You discuss with Sarah over the phone the implications of 
the test, that it identifies mutations responsible for approximately 90% of 
CF, but not all, so therefore doesn’t completely exclude the chance of 
having a child with CF but does greatly reduce the risk. You advise if she is 
found to be a carrier, other family members may also be carriers and further 
guidance and testing could be arranged through the clinical genetics 
department. You gain her consent, record this in her notes and complete 
the form for her to collect and arrange the test. 
Would you feel comfortable explaining autosomal recessive inheritance? 
Could you explain about the risk of having a child affected? Population 
carrier frequency for cystic fibrosis in those of North European heritage is 





If both parents are carriers of an autosomal recessive condition then each 
child has a 1 in 4 chance of inheriting both copies of the affected gene and 
therefore being affected, and a 3 in 4 chance of being unaffected (1 in 4 of 
inheriting two normal copies, and 1 in 2 chance of inheriting one normal and 
one affected copy). In this scenario we know Dave is a carrier, and assuming 
Sarah is of Northern European heritage she has a 1 in 25 chance of being a 
carrier. Therefore their risk of having a child affected by CF with no further 
testing is (1 in 4 x 1 in 25)= 1 in 100. It is important to remember that pregnant 
couples with similar concerns should be offered an urgent referral for timely 
guidance and testing. 
 
Management and support 
 
Despite frequently experiencing a sense of relief once a diagnosis is received, 
this is often tempered/quickly replaced by frustration at a lack of accurate 
information, variability in the level and quality of care and often an absence of 
approved therapies or in some cases restricted access to treatment due to the 
cost. These frustrations with the care pathway are often shared with GPs. 
 
Emerging rare disease drugs  
 
RD treatments are frequently at the vanguard of new and emerging therapies 
and form a significant proportion of new drug approvals.  For example, 
Ataluren for Duchenne muscular dystrophy is a small molecule that “reads 
through” the premature stop codon in the gene and makes a more normally 
functioning protein. Gene therapies have been approved for conditions such 
as a rare inherited retinopathy caused by mutations in the R65 gene and for 
ADA-SCID, a rare form of immunodeficiency. The cost of some of these new 
therapies can be very high and may pose a reimbursement challenge to 
health services. An exciting area that helps address this is the repurposing of 
approved drugs for other indications, including for RDs. 
Primary care can play a role in advising patients on clinical trial opportunities, 
directing patients to patient support groups and ensuring appropriate referral 
to specialist clinics, including nationally commissioned centres. 
 
Caring for rare disease patients in primary care 
 
For many patients, care may be complex involving multiple specialists often at 
distant regional or national specialist centres. Although specialist centres 
improve care and equity of access to emerging therapies and trials, this can 
be to the detriment of local disease knowledge and local health care system 
input for that patient. GPs can help and have a key role in the co-ordination of 
care and management of medically complex patients (RCGP, 2019).They can 
act as a local expert for that patient and their disease, navigating local health 
and social services. A range of resources to help support patients are 
included in Box 4.  For rare disease patients, simple strategies can make a 
tremendous difference, some of these strategies are included in Box 5. 
 
Box 4 and 5 here 
 
 
The future of rare disease in primary care 
 
There is an increasing ability to both diagnose and treat rare diseases. GPs 
currently play a crucial role and are likely to have an increasingly important 
role in this. The definition of a RD is likely to change. More RDs will be 
defined but common diseases will more often be broken into molecularly 
distinct subtypes. Will these subtypes be considered RDs? 
 
Disease identification and diagnosis 
Primary care records and GPs’ skills set are especially well suited to playing a 
greater role in identifying patients with RDs. Enhanced data analytical 
methods are being used, including artificial intelligence (AI), to analyse 
primary care records for patterns of features that suggest a rare disease with 
suggested next steps for investigation (EAHSN, 2019). Primary care research 
databases can also be used to gain greater understanding of the natural 
history of rare diseases and their impact, as well as being used to develop 
predictive tools that intelligently target where resources should be placed to 
screen for such disease. 
 
With greater use of direct to consumer testing (DTC), patients may present 
with genomic information reporting their carrier status for certain rare 
diseases. Although potentially valuable, these tests have limitations and 
frequently lack the sensitivity of carrier testing performed through NHS 
genetics laboratories, identifying the most common pathogenic variants only, 
and thereby potentially giving false reassurance. Would you feel comfortable 
explaining what this means to a patient and know when this may need further 
exploration?  The joint position statement on DTC from the RCGP and BSGM 
may help inform how to approach this scenario. 
www.rcgp.org.uk/policy/rcgp-policy-areas/genomic-position-statement.aspx 
 
The number of diseases included in the NBS will expand, with WGS of all 
newborns likely to be the most economically prudent approach (van Campen 
et al, 2019). However there remain significant issues and uncertainties about 
the natural history of many diseases. Which parts of the WGS should be 
interrogated and for what diseases is less clear and as new genetic variation 
is identified, the significance these differing parts may be unclear and adds 
further uncertainty.  Will GPs be equipped to communicate this complexity 
and uncertainty? 
 
Disease management and therapeutics 
RDs are already managed at nationally commissioned specialist centres, 
often some distance from the patient’s home. Telemedicine and video 
consulting will play a greater role, with remote expert input into local care 
pathways. How will this fit into local health care and what role will there be for 
primary care? Will there be a primary care clinician, a GP with a specialist 
interest, to act as the co-ordinating doctor for a range of medically complex 
patients? This clinician could act as the key doctor for these patients 
incorporating the advice of national and local expertise with their generalist 
knowledge and awareness of local services. 
A growing number of RDs have licensed therapies and clinical trials for 
emerging treatments. These drugs, often at the forefront of therapeutic 
advances and headline making news, are frequently prohibitively expensive. 
How will health care systems afford them and what level of priority should the 




• Rare diseases are individually rare but collectively common 
• Primary care plays a key role in identifying patients who would benefit 
from referral to specialists and their management day-to-day, as well 
as communicating and advocating for these patients between different 
health and social care services 
• “Dare to think rare” and be inquisitive; is there a more plausible 
explanation for your patient’s problems? 
• Use online resources and local experts and clinicians to refine your 
suspicions 
• Consider patients for whom revisiting their diagnosis would be 
worthwhile given advances in disease knowledge and diagnostics  
• Work collaboratively with rare disease patients, they are often experts 
in their disease and how it affects them 
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Box 1. FAMILY GENES 
Scenarios to suspect a rare or genetic disease in primary care 
 
Family history: 3 generation FHx. Multiple affected siblings or individuals in 
multiple generations. (Absence of a FHx does NOT rule out genetic 
causes.) 
 
 G: group of congenital anomalies. Common anatomic variations are 
common; but two or more anomalies are much more likely to indicate 
the presence of a syndrome. 
 E: extreme or exceptional presentation of common conditions. Early 
onset CV disease, cancer, or renal failure. Unusually severe reaction to 
infectious or metabolic stress. Recurrent miscarriage.  
 N: neurodevelopmental delay or degeneration. Developmental delay in 
the paediatric age group carries a very high risk for genetic disorders. 
Developmental regression in children or early onset dementia in adults 
should similarly raise suspicion for genetic etiologies. 
 E: extreme or exceptional pathology. 
 S: surprising laboratory values. Markedly abnormal pathology results. 
 
Is there a more plausible explanation for my patient’s problems? 
(Whelan et al. 2004)  
 
Box 2.  Rare disease diagnostic resources 
 
• MendelApp is a rare disease semantic search engine. Type in 2 
clinical features and it maps to a number of rare disease differential 
diagnoses. Further questions are asked to for further refinement.  
www.mendelian.co 
• The Phenomizer. An online diagnostic engine where clinical terms 
using Human Phenotype Ontology (HPO) terms are combined to 
generate a differential diagnostic list.  
http://compbio.charite.de/phenomizer. 
• Findzebra is a rare disease search engine that has been shown to 
outperform Google. www.findzebra.com.  
• Orphanet a European rare disease resource with information about 









Box 3.  Newborn blood spot screening 
 
Taken when 5 days old (can be up to 8 days old). With test results returned 
within 6 weeks (but sooner if the result is positive). 
 
9 conditions tested for: 
• Sickle cell disease (SCD),  
• Cystic fibrosis (CF),  
• Congenital hypothyroidism (CHT)  
 
and six inherited metabolic diseases (IMDs): 
• Phenylketonuria (PKU),  
• Medium-chain acyl-CoA dehydrogenase deficiency (MCADD), 
• Maple syrup urine disease (MSUD),  
• Isovaleric acidaemia (IVA),  
• Glutaric aciduria type 1 (GA1)  








Box 4. Resources 
• Orphanet a European resource of a range of resources for rare 
diseases.  www.orpha.net/consor/cgi-bin/index.php 
• Genetic Alliance brings together patient organisations for a range of rare 
diseases. They also run SWAN a support network for families with 
undiagnosed genetic conditions.  https://geneticalliance.org.uk 
• GeneReviews. Peer reviewed and updated published articles for a wide 
range of genetic conditions. 
• Unique a charity that provides information for both families and health 
care professionals on chromosomal abnormalities. www.rarechromo.org 
• Medics 4 Rare Diseases (M4RD) an organisation aimed at raising 
awareness and encouraging the engagement of healthcare 
professionals in rare diseases. www.m4rd.org/ 
• National Genomic Test directory 
www.england.nhs.uk/publication/national-genomic-test-directories/ 
• RCGP Genomic webinars  (including a rare disease webinar). 
www.rcgp.org.uk/clinical-and-research/our-programmes/genomics-
webinars.aspx 
• Findacure  a charity to support rare disease charities, encourage and 




Box 5 – Strategies for caring for patients with a rare disease in primary 
care  
• Patient summaries, emergency care plans, or useful recent letters 
highlighted or linked from the patient’s EHR home page can ensure 
the patient feels you understand their disease and challenges. 
Patients and carers often report the emotional strain of having to 
explain their disease repeatedly to different health care 
professionals, and reliving a path to diagnosis that may have been 
traumatic and upsetting. 
• Understanding and appreciation for each other’s expertise. Patients 
and carers are frequently experts in the disease and how it affects 
them. As a GP, you are skilled in managing medical complexity, 
uncertainty and common diseases in your locality. A patient/doctor 
collaboration with shared decision-making in both diagnostic work up 
and management is both rewarding and optimises outcomes for the 
patient.  
• Avoiding the easy assumption that every problem is a result of the 
‘headline’ diagnosis. Rare disease patients have normal disease and 
infections too. For example unrecognised urinary retention, 
constipation or depression are common and treatable, with 
substantial improvements available in both the patient’s quality of life 
and often their apparent disease severity 
• Think holistically, often rare disease patients have complex 
multisystem disease. Don’t assume that others have thought about 
and addressed simple things. Consider a patient from head to toe. 
Do they have dental issues that need addressing? Do they need 
speech and language therapy or dietician involvement? Do they 
need wheelchair services, physiotherapy or OT involvement? Do 
they have or need continence products, are these prescribed or are 
they purchasing themselves?  
• Rare diseases are complex, significant and often life limiting 
diseases. Patients and their families may approach primary care for 
support with the multifaceted nature of these diseases. The care 
demands on can be substantial, with the need for both practical and 
psychological support for the family including their unaffected 
siblings. Signposting to patient advocacy groups (see box 4) can be 
invaluable. Early referral to local hospice services for life-limiting 
conditions, is encouraged. Children’s hospices for example offer not 
only expert symptom management but also respite care, practical 
and psychological support to the whole family. 
 
